Highlights of cardiovascular disease studies presented at the 2021 European Society of Cardiology Congress

Document Type



Office of the Provost; Cardiology


Purpose of review: This review highlights select studies presented at the virtual 2021 European Society of Cardiology (ESC) Congress.
Recent findings: Reviewed studies assess single photon emission computed tomography, positron emission tomography, magnetic resonance imaging in coronary artery disease (PACIFIC-II); empagliflozin in heart failure with preserved ejection fraction (EMPEROR-Preserved); dapagliflozin in chronic heart failure (DAPA-HF); proprotein convertase subtilisin/kexin type 9 inhibitor and its lipid lowering effects (NATURE-PCSK9); fixed-dose combination therapies with or without aspirin in primary prevention; overview of contrasting results between REDUCE-IT versus STRENGTH trials; Quadruple UltrA-low-dose tReaTment for hypertension (QUARTET); evolocumab and changes in plaque composition on optical coherence tomography (HUYGENS); and low-dose rivaroxaban during the acute phase of acute coronary syndrome (H-REPLACE). Research presented at the 2021 ESC Congress shows promise in reducing burden of cardiovascular disease and reinforces the value of cardiovascular disease prevention.


Pagination are not provided by the author/publisher. This work was published before the author joined Aga Khan University.

Publication (Name of Journal)

Current atherosclerosis reports